ValiRx PLC

("ValiRx" or the "Company")

Inaphaea BioLabs Operational Update

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, announces an operational update from the Company's wholly owned subsidiary, Inaphaea BioLabs Limited ("Inaphaea").

Inaphaea has entered into an agreement with the Virtual CRO services company OncoBone Limited ("OncoBone") whereby clients of OncoBone can access Inaphaea services.  OncoBone offers a service to virtual biotech and other biopharma clients whereby OncoBone designs and commissions pre-clinical work on behalf of the client.  To conduct the laboratory work, OncoBone engages with a range of pre-clinical Contract Research Organisations ("CROs") to execute on the experimental designs that OncoBone has developed.  Inaphaea is now confirmed as an OncoBone supplier of cell-based assays.

Additionally, Inaphaea is pleased to report that the cell-based assay services are now listed on scientist.com, a database of CROs that can be used by biotechnology and pharmaceutical companies to search for scientific capabilities.

Dr Suzy Dilly, CEO at ValiRx explains "This operational update demonstrates the progress made by Inaphaea towards generating contract revenues. We're particularly excited by the prospect of working with OncoBone due to the innovative nature of their Virtual CRO service."

The Directors of the Company take responsibility for this announcement.

For more information, please contact:

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. 

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

About Inaphaea BioLabs

Inaphaea BioLabs is a new pharmaceutical services company, based in Nottingham (UK), offering cell-based assays specialising in oncology and women's health.  Our aim is to improve the translation of early drug discovery projects towards the clinic. Driven by a desire to generate deeper biological understanding of drug candidates in discovery and preclinical phases of development, Inaphaea will provide testing services that generate the necessary data, analysis and insights to aid decision making in translational drug development.

Spun out from ValiRx PLC, the core team within Inaphaea have a strong background of preclinical and clinical drug development, and of understanding both the commercial and scientific needs of the service users from both sides of the table.

Inaphaea will offer a range of services across all areas of cell-based assays, including efficacy and selectivity of activity against cancer cells; mechanistic and binding assays; and measurements of production of cell markers and hormones.  Inaphaea's services will evolve over time to incorporate new techniques and technologies with the ambition to improve biological understanding and translatability of early discovery in drug development.

For further information, visit www.inaphaea.com

 About OncoBone

OncoBone offers scientific expertise to pharmaceutical and biotech industry and their service providers globally. OncoBone representatives have a long history of working in CRO business and a large global network of high-quality CRO partners. OncoBone utilizes this extensive experience to guide pharma/biotech companies in need of CRO services to work with the best fit CRO partners. OncoBone can assist its pharma/biotech clients in their preclinical-stage programs through its Virtual CRO concept, where OncoBone subcontracts the work to its CRO partners and manages the projects internally.

About Scientist.com

Scientist.com's mission is to empower and connect scientists worldwide. The company's digital research platform combines a custom-built, cloud native technology stack with white-glove customer and scientific support to enable scientists to run more innovative experiments in less time and at lower cost. Scientist.com leverages internally developed machine learning models to provide actionable insights that improve operational efficiency and effective research management. Scientist.com connects the world's top pharmaceutical companies, biotechnology companies and the US National Institutes of Health (NIH) to the world's largest network of scientific suppliers.

Visit scientist.com to learn more.

Cautionary statement

Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.